GEN Exclusives

More »

GEN News Highlights

More »
Feb 2, 2010

Phylogica Taps Isogenica’s In Vitro Display Technology

  • Australian-based biopharmaceutical company Phylogica will use Isogenica’s CIS display technology to optimize the performance of three of its lead compounds targeting CD40 ligand (CD40L). CD40L is a key protein involved in many inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

    CIS display, an in vitro display technology, allows the generation of polypeptide libraries of unprecedented size and complexity, according to Isogenica. It is then possible to select polypeptides with high affinity and specificity for most targets, the company continues.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?